Funding for a Successful Professional Career as Physician Performing Research

The Else Kröner-Fresenius-Stiftung foundation wants to support the medical faculties and university hospitals in Germany within the framework of group research programmes.
Research at Internal Medicine II Clinic, Uniklinik Freiburg

This programme allows young, extremely talented physicians in scientific fields to have an optimal environment for fostering their research work; to enable entry to a successful professional career as clinician scientist.

The Else Kröner Forschungskollegien for Physicians are an innovative tool in the German funding landscape and are geared to research-intensive university hospitals. The scholars can focus fully on their research project for one to two years and work on a joint subject area within a scientifically excellent research group. An accompanying curriculum also creates an extensive knowledge base and establishes contacts with international experts. The maximum funding volume per group research programme amounts to €1.0 million for three years, with the option of a second funding period.

Anne Asschenfeldt
Application submission for ongoing project funding, fellowships and advancement programmes
Portrait Anne Asschenfeldt
Default Image Contact module

Overview of Current Group Research Programmes

Prof. Dr. Jörg C. Kalff, Bonn University Hospital

Innate immunity and chronic organ dysfunction. Granted in 2011 for 3 years; one-time extension for a further 3 years following a successful review in 2014.

Prof. Dr. Stephan Stilgenbauer, Ulm University Hospital

Stem cells, aging and malignant transformation. From experimental model to clinical application. Ggranted in 2011 for 3 years; one-time extension for a further 3 years following a successful review in 2014.

Prof. Dr. Dr. Andreas Beilhack, Würzburg University Hospital

Interdisciplinary translational immunology. Granted in 2011 for 3 years; one-time extension for a further 3 years following a successful review in 2014.

Prof. Dr. Gerd Walz, Freiburg University Hospital

Renal dysfunction as a complication of systemic diseases. Granted in 2013 for 3 years; one-time extension for a further 3 years following a successful review in 2016.

Prof. Dr. Ulrike Protzer, Technical University of Munich

Microbial triggers as cause of diseases. Granted in 2013 for 3 years; one-time extension for a further 3 years following a successful review in 2016.

Prof. Dr. Christoph Klein, LMU Munich Paediatric Clinic and Polyclinic in the Dr. von Hauner’schen Children’s Hospital

Rare diseases of the immune system - from the pathophysiology to the development of new treatment strategies. Granted in 2013 for 3 years; one-time extension for a further 3 years following a successful review in 2016.

Prof. Dr. Matthias Dobbelstein, University Medical Center Göttingen

Molecular therapy and prediction in colorectal carcinoma. Granted in 2014 for 3 years; one-time extension for a further 3 years following a successful review in 2018.

Prof. Dr. Simone Fulda, University Hospital Frankfurt a. Main

Targeted therapy strategies in oncology ("Targeted Therapies"): from the molecular basis to clinical application. Ggranted in 2014 for 3 years; one-time extension for a further 3 years following a successful review in 2018.

Prof. Dr. Thomas Fischer, University Hospital Magdeburg

The role of the inflammatory microenvironment for the development of preneoplasia: from the molecular signals to new treatment strategies. Granted in 2014 for 3 years; one-time extension for a further 3 years following a successful review in 2018.

Prof. Dr. Ghazaleh Tabatabai, University Hospital Tübingen

Therapy resistance in solid tumours. Granted in 2016 for 3 years.

Prof. Dr. Marion Subklewe, LMU University Hospital of Munich

Immunotherapy in the treatment of cancer: mechanisms of action and resistance. Granted in 2016 for 3 years.

Prof. Dr. Peter Falkai, LMU University Hospital of Munich

Translational psychiatry. Granted in 2016 for 3 years.

Prof. Dr. Otto Witte, University Hospital Jena

Aging and disease: translational analysis of therapeutic interventions (AntiAge). Granted in 2016 for 3 years.

Prof. Dr. Ali El-Armouche, University Hospital Dresden

Dynamics of the phosphoproteome: Novel working principles and interdisciplinary concepts for the therapy of cancer, neurodegenerative disorders and diabetes. Granted in 2017 for 3 years.

Prof. Dr. Peter Oefner, University Hospital Regensburg

Interdisciplinary translational Immuno-Oncology. Granted in 2017 for 3 years.

Prof. Dr. Heike Pahl, University Hospital Freiburg

Immunological Causes and Therapies of Cancer. Granted in 2017 for 3 years.

Prof. Dr. Christian Reinhardt, University Hospital Köln

Targeting therapy-induced dynamic alterations within the cancer genome. Granted in 2017 for 3 years.